Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Wholesale Dealer President Deeply Sorry for Letting Fake Harvoni into Supply Chain
To read the full story
Related Article
- Tokyo Govt Orders 2 “Cash-and-Carry” Dealers to Suspend Business
April 14, 2017
- 2 Kansai Medico Pharmacy Outlets Ordered to Suspend Biz
March 17, 2017
- Tokyo, Osaka Govts Issue Biz Improvement Order to Dealers over Fake Harvoni
March 14, 2017
- 3 Kansai Medico Pharmacies Slapped with Biz Improvement Order over Fake Harvoni
March 7, 2017
- MHLW Mulls Administrative Penalties, Tighter Regulations after Counterfeit Harvoni Case
February 14, 2017
- MHLW Wraps Up Probe into Fake Harvoni after Distribution Routes “Most Likely” Identified
February 2, 2017
- MHLW Pins Down Distribution Routes for Harvoni Counterfeits; Composition of Fake Pills Identified
February 1, 2017
- Kansai Medico Used Non-Official Harvoni Dealer for Cheaper Price
January 25, 2017
- Counterfeit Harvoni Found in Tokyo Too, Route Identified for a Nara Bottle
January 24, 2017
- Counterfeit Harvoni Discovered in Nara Pharmacy, MHLW Investigating Route of Entry into Distribution
January 18, 2017
BUSINESS
- Moderna Set to Develop Cancer Vaccines, Rare Disease Therapies in Japan: New Local Chief
May 10, 2024
- Jardiance Positive in Japanese CKD Patients Too: Subgroup Analysis
May 10, 2024
- Takeda’s Operating Profit Dips by More than Half in FY2023
May 10, 2024
- Japan Ethical Drug Sales Down 2.4% in March: Crecon
May 10, 2024
- Keytruda Best-Selling Drug in Japan for 7th Month in April: Encise
May 10, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…